<DOC>
	<DOCNO>NCT01839500</DOCNO>
	<brief_summary>This prospective , multi-center , non-interventional study evaluate efficacy safety Herceptin ( trastuzumab ) routine clinical practice Chinese patient gastric gastro-oesophageal cancer . Treatment pattern clinical outcome patient gastric cancer China evaluate . Data collect eligible patient 6 year .</brief_summary>
	<brief_title>EVIDENCE : A Non-Interventional Study Treatment Clinical Outcomes Chinese Patients With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Histologically confirm cancer stomach gastrooesophageal junction recurrent disease within 6 month date recruitment Documented patient trackable medical record HER2 IHC status know Cohort I/II/IV : Patients mGC : recurrent metastatic disease inoperable locally advanced disease Cohort III/V : Patients operable nonmGC : TxNxM0 ( accord AJCC edition 7th ) Patients receive regimen blind trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>